Multiomics Data Analysis and Identification of Immune-Related Prognostic Signatures With Potential Implications in Prognosis and Immune Checkpoint Blockade Therapy of Glioblastoma by Shuai Ma, Shuai Ma, Fang Wang, Nan Wang, Jiaqi Jin, Yixu Ba, Hang Ji, Jianyang Du, Shaoshan Hu

“…Then, we used three hub genes to construct an IRPM for GBM and clarify the immunity, mutation, and methylation characteristics.ResultsSurvival analysis of patients undergoing anti-program cell death protein 1 (anti-PD-1) therapy showed that overall survival was superior in the low-risk group than in the high-risk group. …”
Get full text

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy by Weijie Ma, Barbara M. Gilligan, Jianda Yuan, Tianhong Li

“…Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1) have demonstrated acceptable toxicity, promising clinical responses, durable disease control, and improved survival in some patients with advanced melanoma, non-small cell lung cancer (NSCLC), and other tumor types. …”
Get full text

Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas by Robert Roskoski, Jr.

“…The monoclonal antibody immune checkpoint inhibitor nivolumab (targeting programed cell death protein 1, PD1) was approved for the treatment of RCCs in 2015. …”
Get full text

A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-Like Properties and Invasion in Human Bladder Cancer by Junlan Zhu, Yang Li, Yisi Luo, Jiheng Xu, Huating Liufu, Zhongxian Tian, Chao Huang, Jingxia Li, Chuanshu Huang

“…Programmed cell death protein 1 (PD-1) and its ligand PD-L1 blockade have been identified to target immune checkpoints to treat human cancers with durable clinical benefit. …”
Get full text

Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo by Xiupeng Ye, Meijing Liu, Cuicui Lv, Yeqiong Li, Lan Chen, Jin Zhang, Juan Mu, Qi Deng

“…Methods: We selected a low effect-target ratio (E:T = 1:3) to study this synergistic effect in vitro. The programed cell death protein 1 (PD-1) expression in CD19 CAR-T cells and immune phenotype of T lymphocytes were analyzed by flow cytometry (FCM). …”
Get full text

Folliculotropic Mycosis Fungoides Is Associated with Decreased PD1 Staining Compared with Classic Mycosis Fungoides by Haiming Tang, Kristin J. Rybski, Yi Luan, Bruce R. Smoller

“…Programmed cell death protein 1 (PD-1) plays a pivotal role in immune system regulation, with its expression levels linked to malignancy prognosis. …”
Get full text

Longitudinal Changes in CD4⁺, CD8⁺ T Cell Phenotype and Activation Marker Expression Following Antiretroviral Therapy Initiation among Patients with Cryptococ... by Alice Bayiyana, Samuel Okurut, Rose Nabatanzi, Godfrey Zziwa, David R. Boulware, Fredrick Lutwama, David Meya

“…There was variation in the expression of immunophenotypic markers defining central memory (CD27⁺CD45R0⁺), effector memory (CD45R0⁺CD27^−), immune activation (CD38⁺ and Human Leucocyte Antigen DR (HLA-DR⁺), and exhaustion (Programmed cell death protein one (PD-1) in the CD4⁺ T cell subset. …”
Get full text

Identification of antibodies cross-reactive with woodchuck immune cells and activation of virus-specific and global cytotoxic T cell responses by anti-PD-1 and anti-PD-L1 in experi... by Christopher P. Corkum, Louisa L. Wiede, Cara L.-A. Ruble, Jiabin Qiu, Patricia M. Mulrooney-Cousins, Meredith A. Steeves, David E. Watson, Tomasz I. Michalak

“…The confirmed antibodies against programed cell death protein-1 (PD-1) and its ligand (PD-L1) were examined for ex vivo ability to activate WHV-specific, global and bystander cytotoxic T cells (CTLs) in chronic hepatitis and asymptomatic infection persisting after self-resolved acute hepatitis. …”
Get full text

A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors by Jessica Castrillon Lal, Sherry-Ann Brown, Patrick Collier, Feixiong Cheng

“…Results We found that myocarditis was significantly associated with patients receiving anti-program cell death protein 1 (PD-1) or anti-program death ligand 1 (PD-L1), odds ratio (OR) = 23.86 (95% confidence interval [CI] 11.76–48.42, (adjusted p-value) q <  0.001), and combination immunotherapy, OR = 7.29 (95% CI 1.03–51.89, q = 0.047). …”
Get full text